Reference20 articles.
1. Osimertinib with or without chemotherapy in EGFR mutated advanced NSCLC;Blanchard;N Engl J Med,2023
2. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer;Greenhalgh;Cochrane Database Syst Rev,2021
3. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis;Papadimitrakopoulou;Ann Oncol,2020
4. And still they come over troubled waters: can Asia's third-generation EGFR tyrosine kinase inhibitors (furmonertinib, aumolertinib, rezivertinib, limertinib, befotertinib, SH-1028, and lazertinib) affect global treatment of EGFR+ NSCLC;Lau;J Thorac Oncol,2022
5. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study;Passaro;Ann Oncol,2024
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献